Envestnet Asset Management Inc. Purchases 60,336 Shares of Genmab A/S Sponsored ADR $GMAB

Envestnet Asset Management Inc. increased its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 8.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 809,939 shares of the company’s stock after buying an additional 60,336 shares during the period. Envestnet Asset Management Inc. owned about 0.13% of Genmab A/S worth $24,841,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in GMAB. Blue Trust Inc. lifted its holdings in shares of Genmab A/S by 33.2% during the second quarter. Blue Trust Inc. now owns 9,871 shares of the company’s stock worth $204,000 after purchasing an additional 2,458 shares during the period. Vanguard Personalized Indexing Management LLC raised its position in Genmab A/S by 24.7% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 52,684 shares of the company’s stock worth $1,088,000 after purchasing an additional 10,426 shares during the last quarter. CWM LLC lifted its holdings in Genmab A/S by 50.5% during the 2nd quarter. CWM LLC now owns 1,797 shares of the company’s stock worth $37,000 after buying an additional 603 shares during the period. Yousif Capital Management LLC grew its position in shares of Genmab A/S by 7.8% in the 2nd quarter. Yousif Capital Management LLC now owns 10,943 shares of the company’s stock valued at $226,000 after buying an additional 790 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its stake in shares of Genmab A/S by 200.8% in the second quarter. Caitong International Asset Management Co. Ltd now owns 5,809 shares of the company’s stock valued at $120,000 after buying an additional 3,878 shares during the period. 7.07% of the stock is owned by institutional investors.

Genmab A/S Price Performance

Shares of GMAB opened at $29.59 on Friday. Genmab A/S Sponsored ADR has a one year low of $17.24 and a one year high of $35.43. The company has a market cap of $19.01 billion, a PE ratio of 12.59, a P/E/G ratio of 17.64 and a beta of 0.90. The stock has a 50-day moving average of $32.39 and a 200-day moving average of $29.61.

Wall Street Analyst Weigh In

GMAB has been the topic of a number of recent analyst reports. Johnson Rice reaffirmed a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Zacks Research downgraded shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. Truist Financial reiterated a “buy” rating and set a $48.00 price objective (down from $49.00) on shares of Genmab A/S in a research report on Thursday, November 6th. Wall Street Zen downgraded Genmab A/S from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $39.00 price objective on shares of Genmab A/S in a research note on Wednesday, January 28th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Genmab A/S has a consensus rating of “Moderate Buy” and an average price target of $43.33.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.